The selective histamine H1-receptor agonist 2-(3-trifluoromethylphenyl)histamine increases waking in the rat.
The effects of the selective histamine H1-receptor agonist, 2-(3-trifluoromethylphenyl)histamine, were studied in rats implanted with electrodes for chronic sleep recordings. 2-(3-Trifluoromethylphenyl)histamine (80-120 micrograms) injected into the left lateral ventricle increased wakefulness, whereas slow wave sleep was reduced. Pretreatment with pyrilamine (2.0 mg/kg) prevented the effects of the H1-receptor agonist on wakefulness and slow wave sleep. Our results further support the involvement of histamine in the modulation of the waking state.
Monti
J M
JM
Department of Pharmacology and Therapeutics, School of Medicine, Clinics Hospital, Montevideo, Uruguay.
Jantos
H
H
Leschke
C
C
Elz
S
S
Schunack
W
W
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004567:Electrodes, Implanted; D006632:Histamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D017442:Histamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008297:Male; D011738:Pyrilamine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012890:Sleep / Q000187:drug effects; D014851:Wakefulness / Q000187:drug effects*
C092716:2-(3-trifluoromethylphenyl)histamine; D017442:Histamine Agonists; D006632:Histamine; D011738:Pyrilamine